Indaptus Therapeutics opened lower at $3.15, compared with its previous close of $3.21. In the last trading session, the stock traded between $3.01 and $3.15. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Indaptus Therapeutics is now worth
$ 1.53
Resulting in a loss of
$ 98.47 (98.47%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.07 (-2.02%)
Day High
$3.15
Day Low
$3.01
Day Open
$3.15
Prev Close
$3.21
Volume
91,323
1W Return
-4.52%
1M Return
28.63%
3M Return
162.74%
6M Return
78.69%
1Y Return
15.62%
Fundamentals
Market Cap ($ Mn)
483
PE Ratio
-
PB Ratio
13.47
PEG Ratio
-
ROE
-813.23%
ROCE
-812.60%
EPS (TTM)
$-0.02
Investment Returns
1 Week
-4.52%
1 Month
28.63%
3 Months
162.74%
6 Months
78.69%
9 Months
76.69%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
Updates
10Sep
Indaptus Therapeutics raises ~$24M via private placement for R&D
Indaptus Therapeutics placed 20,338,974 shares in a private placement. Gross proceeds from the transaction total approximately $24 million. Funds will support working capital and general corporate purposes. Capital allocated to R&D for a neural-network-based sleep device. Company aims for potential future FDA submission based on preclinical data.
2mo ago
18Aug
Indaptus Therapeutics files prospectus for resale of 58.9M shares
Indaptus Therapeutics filed an SEC prospectus for the resale of 58,895,000 common stock shares by selling stockholders. This corporate action allows existing holders to liquidate positions in the secondary market without direct capital infusion to the firm.
2mo ago
13Aug
Indaptus Therapeutics Q2 EPS beats estimate as loss narrows
Indaptus Therapeutics reported Q2 2026 EPS of $(0.02), beating the $(1.57) estimate by 98.73%. Net loss narrowed to $1.8 million from $5.2 million in Q2 2025, driven by an 83% drop in R&D costs after discontinuing its primary clinical program. The company holds $11.6 million in liquid assets following a $12.0 million private placement.
3mo ago
27Jun
Indaptus files prospectus for resale of 18.86M shares
Indaptus Therapeutics has filed a prospectus with the SEC for the resale of up to 18.86 million shares of common stock by selling stockholders, outlining the regulatory framework for the distribution of these existing equity holdings.
